Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice

Scritto il 29/05/2026
da Furio Colivicchi

Nutr Metab Cardiovasc Dis. 2026 Apr 30:104777. doi: 10.1016/j.numecd.2026.104777. Online ahead of print.

ABSTRACT

AIMS: This viewpoint discusses the current role of bempedoic acid in clinical practice.

DATA SYNTHESIS: Randomized clinical trials have shown bempedoic acid efficacy in both reducing LDL-C levels and major cardiovascular adverse events. This evidence has led to the inclusion of bempedoic acid among the lipid-lowering therapies with demonstrated clinical efficacy and recommended by the last update of European Society of Cardiology guidelines on dyslipidaemia management to prevent cardiovascular disease.

CONCLUSIONS: Bempedoic acid is an important therapeutic option that overcomes some limitations of statins and allows to further reduce the global burden of atherosclerotic cardiovascular disease.

PMID:42215415 | DOI:10.1016/j.numecd.2026.104777